Mustafa ATMACA, Bora GÜLHAN, Emine ATAYAR, Aysun Karabay BAYAZIT, Cengiz CANDAN, Mustafa ARICI, Rezan TOPALOĞLU, Fatih ÖZALTIN

Long-term follow-up results of patients with ADCK4 mutations who have been diagnosed in the asymptomatic period: effects of early initiation of CoQ10 supplementation

ADCK4-related glomerulopathy is a recently recognized clinical entityassociated with insidious onset in young children and a high potentialto progress to chronic kidney disease in adolescents. Early initiation ofexogenous coenzyme Q10 (CoQ10) supplementation in the asymptomaticperiod could be protective on renal functions. In the present study, we aimed toinvestigate long-term follow-up of patients that we have diagnosed during theasymptomatic period and in whom we started CoQ10 treatment. We analyzedlong-term effects of CoQ10 on proteinuria and estimated glomerular filtrationrate (eGFR) in this patient population. A total of 8 patients (4 female, 4 male)from 6 different families were included. The mean age at diagnosis and atlast visit were 16.8±11.2 years and 20.7±11.7 years, respectively. None ofthe patients had extrarenal system involvement. At the time of initiationof treatment; median eGFR was 107.8 ml/min/1.73 m2, median proteinuriawas 1008 mg/m2/day. After a median follow-up period of 25.3±5.8 months,median proteinuria decreased to 318.5 mg/m2/day (p=0.03) and median eGFRremained stable at 99.6 ml/min/1.73 m2 (p=0.21). Coenzyme Q10 treatmentis effective for reducing proteinuria and seems to be renoprotective.

PDF

___

1. Wang F, Zhang Y, Mao J, et al. Spectrum of mutations in Chinese children with steroid-resistant nephrotic syndrome. Pediatr Nephrol 2017; 32: 1181-1192.

2. Ozaltin F. Primary coenzyme Q10 (CoQ10) deficiencies and related nephropathies. Pediatr Nephrol 2014; 29: 961-969.

3. Desbats MA, Lunardi G, Doimo M, Trevisson E, Salviati L. Genetic bases and clinical manifestations of coenzyme Q10 (CoQ 10) deficiencies. J Inherit Metab Dis 2015; 38: 145-156.

4. Korkmaz E, Lipska-Ziętkiewicz BS, Boyer O, et al; PodoNet Consortium. ADCK4-associated glomerulopathy causes adolescence-Onset FSGS. J Am Soc Nephrol 2016; 27: 63-68.

5. Ashraf S, Gee HY, Woerner S, et al. ADCK4 mutations promote steroid-resistant nephrotic syndrome through CoQ10 biosynthesis disruption. J Clin Invest 2013; 123: 5179-5189.

6. Atmaca M, Gulhan B, Korkmaz E, et al. Follow-up results of patients with ADCK4 mutations and the efficacy of CoQ10 treatment. Pediatr Nephrol 2017; 32: 1369-1375.

7. Schwartz GJ, Muñoz A, Schneider MF, et al. New equations to estimate GFR in children with CKD. J Am Soc Nephrol 2009; 20: 629-637.

8. Levey AS, Coresh J, Greene T, et al; Chronic Kidney Disease Epidemiology Collaboration. Using standardized serum creatinine values in the modification of diet in renal disease study equation for estimating glomerular filtration rate. Ann Intern Med 2006; 145: 247-254.

9. Rötig A, Appelkvist EL, Geromel V, et al. Quinoneresponsive multiple respiratory-chain dysfunction due to widespread coenzyme Q10 deficiency. Lancet 2000; 356: 391-395.

10. Salviati L, Sacconi S, Murer L, et al. Infantile encephalomyopathy and nephropathy with CoQ10 deficiency: a CoQ10-responsive condition. Neurology 2005; 65: 606-608.

11. Diomedi-Camassei F, Di Giandomenico S, Santorelli FM, et al. COQ2 nephropathy: a newly described inherited mitochondriopathy with primary renal involvement. J Am Soc Nephrol 2007; 18: 2773-2780.

12. Montini G, Malaventura C, Salviati L. Early coenzyme Q10 supplementation in primary coenzyme Q10 deficiency. N Engl J Med 2008; 358: 2849-2850.

13. Stotter BR, Ferguson MA. Should ACE inhibitors and ARBs be used in combination in children? Pediatr Nephrol 2019; 34: 1521-1532.